Home / Business and Economy / Moderna Stock Plummets on Leaked Cancer Vaccine Trial Data
Moderna Stock Plummets on Leaked Cancer Vaccine Trial Data
22 Oct
Summary
- Moderna's stock dropped nearly 24% following early release of trial results.
- Cancer vaccine combination reduced melanoma recurrence risk by 42%.
- Embargo violation disclosure rattled investors, overshadowing positive data.
Moderna Inc. stock saw a sharp decline of approximately 24.0% in mid-day trading. This downturn followed the apparent early, unauthorized publication of embargoed Phase 3 trial results for its personalized mRNA cancer vaccine. The data stemmed from the INTerpath-001 trial, which evaluated an autogene in combination with Merck's Keytruda immunotherapy for melanoma patients.
The released figures, though clinically encouraging, were shared prematurely on a medical news website before their official presentation at the European Society for Medical Oncology congress. The combination therapy demonstrated a 42% reduction in the risk of melanoma recurrence or death compared to Keytruda alone. Despite this positive clinical outcome, the manner of disclosure, an apparent embargo violation, significantly impacted investor confidence and led to a volatility-related trading halt in MRNA shares.
